About Regenesis
Regenesis is a company based in Scottsdale (United States) founded in 1996. Regenesis has raised $13.32 million across 4 funding rounds from investors including Solstice Capital, Fulcrum Equity Partners and TGap Ventures. Regenesis offers products and services including Reprieve, Provant, and Infinity. Regenesis operates in a competitive market with competitors including Organogenesis, Sofregen, Encellin, BioTissue and Reapplix, among others.
- Headquarter Scottsdale, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.32 M (USD)
in 4 rounds
-
Latest Funding Round
$5.2 M (USD), Series C
Jun 10, 2011
-
Investors
Solstice Capital
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Regenesis
Regenesis offers a comprehensive portfolio of products and services, including Reprieve, Provant, and Infinity.
Electromagnetic therapy for non-drug home pain relief.
Home-based system for pain management support.
Advanced tool for electromagnetic pain relief.
Funding Insights of Regenesis
Regenesis has successfully raised a total of $13.32M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $5.2 million completed in June 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Regenesis
Regenesis has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Solstice Capital, Fulcrum Equity Partners and TGap Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across the United States.
|
Locked | Locked | Locked | |
|
US focused seed & early stage Micro VC firm
|
Locked | Locked | Locked | |
|
TGap Ventures is engaged in venture capital investments for startups.
|
Locked | Locked | Locked |
Investor details for Regenesis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Regenesis
Investment portfolio details for Regenesis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Regenesis
Detailed financials for Regenesis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Regenesis Comparisons
Peer comparison for Regenesis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Regenesis
Regenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Organogenesis, Sofregen, Encellin, BioTissue and Reapplix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
|
| Locked | Locked | Locked |
Silk-derived biomaterials are developed for soft tissue repair in surgery.
|
|
| Locked | Locked | Locked |
Developer of regenerative materials
|
|
| Locked | Locked | Locked |
Regenerative biologic therapies for eye care are developed and provided.
|
|
| Locked | Locked | Locked |
Developer of patch system for wound healing
|
|
| Locked | Locked | Locked |
Synthetic electrospun scaffolds are provided for regenerative medical uses.
|
Detailed competitors of Regenesis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Regenesis
Complete news archive for Regenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regenesis
Regenesis was founded in 1996 and raised its 1st funding round 6 years after it was founded.
Regenesis is headquartered in Scottsdale, United States. It is registered at Scottsdale, Arizona, United States.
Tom Eisiminger is the current CEO of Regenesis.
Regenesis is a funded company, having raised a total of $13.32M across 4 funding rounds to date.
Regenesis was founded in 1996 in Scottsdale, United States, and operates in the medical devices sector focused on pain management. At-home solutions without drugs are delivered through electromagnetic shortwave diathermy therapy devices. Products offered include Reprieve 60, Reprieve Duo, and Reprieve, which support patient care in non-clinical settings across the United States.
Regenesis's top competitors include Organogenesis, GeniPhys and Acera Surgical.
Regenesis offers Reprieve, Provant, and Infinity.
Regenesis has 5 investors. Key investors include Solstice Capital, Fulcrum Equity Partners, TGap Ventures, Village Ventures, and Valley Ventures.